Omnicell Inc (OMCL)

Currency in USD
38.19
-8.50(-18.21%)
Real-time Data·
Earnings results expected today
OMCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
36.9540.16
52 wk Range
22.6655.00
Key Statistics
Prev. Close
46.69
Open
39.69
Day's Range
36.95-40.16
52 wk Range
22.66-55
Volume
837.45K
Average Volume (3m)
532.84K
1-Year Change
-14.0829%
Book Value / Share
26.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OMCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
58.86
Upside
+54.12%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

Omnicell Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Omnicell Company Profile

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Omnicell Inc SWOT Analysis


Financial Rebound
Omnicell surpasses Q2 expectations, raising full-year guidance and sparking investor confidence amid improving hospital capital expenditure trends
Strategic Evolution
Explore Omnicell's expansion into specialty pharmacy and the potential impact on Advanced Services revenue streams in a rapidly growing market segment
Operational Overhaul
New COO appointment signals focus on cost reduction and operational efficiency, potentially driving long-term profitability and market competitiveness
Market Positioning
Analysts set price targets ranging from $39 to $58, reflecting varied outlooks on Omnicell's ability to navigate industry challenges and capitalize on healthcare tech trends
Read full SWOT analysis

Omnicell Inc Earnings Call Summary for Q4/2025

  • Omnicell's Q4 2025 EPS of $0.40 missed forecasts by 20%, while revenue reached $314 million, slightly exceeding expectations, causing shares to plummet 14.69% in pre-market trading.
  • Full-year 2025 revenue increased 6.6% to $1.185 billion, with service revenue growing 8% while product revenue declined 1%, indicating a shift toward recurring revenue streams.
  • CEO Randall Lipps emphasized strategic focus on sustainable, higher-margin business models with recurring revenues and cloud-based enterprise solutions.
  • For 2026, Omnicell projects revenue between $1.215-1.255 billion and non-GAAP EPS of $1.65-1.85, with plans to launch the Titan XT platform in H2 2026.
  • Cash and equivalents fell to $197 million from $369 million in 2024, while the company faces challenges from supply chain disruptions and increased competition in healthcare technology.
Last Updated: 05/02/2026, 15:02
Read Full Transcript

Compare OMCL to Peers and Sector

Metrics to compare
OMCL
Peers
Sector
Relationship
P/E Ratio
105.2x28.4x−0.5x
PEG Ratio
0.420.240.00
Price/Book
1.7x4.2x2.6x
Price / LTM Sales
1.8x4.1x3.3x
Upside (Analyst Target)
53.5%5.5%46.2%
Fair Value Upside
Unlock5.7%6.6%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 58.86
(+54.12% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BofA Securities
Buy70.00+83.78%53.00Upgrade04/02/2026
Benchmark
Buy60.00+57.52%50.00Maintain02/02/2026
BofA Securities
Hold53.00+39.14%46.00Maintain16/01/2026
KeyBanc
Buy60.00+57.52%-Upgrade08/01/2026
Wells Fargo
Sell52.00+36.52%43.00Maintain05/01/2026

Earnings

Latest Release
Feb 05, 2026
EPS / Forecast
0.40 / 0.50
Revenue / Forecast
314.00M / 313.39M
EPS Revisions
Last 90 days

People Also Watch

95.41
CHDN
-0.08%
148.39
VICR
-2.43%
30.180
AROC
+0.63%
285.05
LECO
-0.27%
199.54
PLXS
+1.66%

FAQ

What Is the Omnicell (OMCL) Share Price Today?

The live Omnicell share price today is 38.19

What Stock Exchange Does Omnicell (OMCL) Trade On?

Omnicell is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Omnicell?

The stock symbol (also called a 'ticker') for Omnicell is "OMCL."

What Is the Current Omnicell Market Cap?

As of today, Omnicell market capitalisation is 1.72B.

What Is Omnicell's (OMCL) Earnings Per Share (TTM)?

The Omnicell EPS is currently 0.43 (Trailing Twelve Months).

When Is the Next Omnicell Earnings Date?

Omnicell's next earnings report will be released on 05 Feb 2026.

Is OMCL a Buy or Sell From a Technical Analyst Perspective?

Based on today's Omnicell moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Omnicell Stock Split?

Omnicell has split 0 times. (See the OMCL stock split history page for full effective split date and price information.)

How Many Employees Does Omnicell Have?

Omnicell has 3600 employees.

What is the current trading status of Omnicell (OMCL)?

As of 05 Feb 2026, Omnicell (OMCL) is trading at a price of 38.19, with a previous close of 46.69. The stock has fluctuated within a day range of 36.95 to 40.16, while its 52-week range spans from 22.66 to 55.00.

What Is Omnicell (OMCL) Price Target According to Analysts?

The average 12-month price target for Omnicell is USD58.86, with a high estimate of USD70 and a low estimate of USD52. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +54.12% Upside potential.

What Is the OMCL Premarket Price?

OMCL's last pre-market stock price is 39.83. The pre-market share volume is 2,860.00, and the stock has decreased by -6.86, or -14.69%.

What Is the OMCL After Hours Price?

OMCL's last after hours stock price is 47.28, the stock has decreased by 0.59, or 1.26%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.